Gallium-68-SH 7139

Drug Profile

Gallium-68-SH 7139

Alternative Names: Ga68-SH-7139; Gallium-68-SH7139

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator SHAL Technologies
  • Developer SHAL Technologies; Zentralklinik Bad Berka
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Jul 2015 Phase-0 for Non-Hodgkin's lymphoma (Diagnosis) in Germany (IV) before July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top